Evaluating the ability of zoledronic acid to reduce the rate of subsequent osteoporotic fractures after a hip fracture
Latest Information Update: 02 Jun 2021
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone resorption; Fracture; Osteoporosis
- Focus Therapeutic Use
- Acronyms HORIZON-RFT
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Jun 2021 Results of post hoc analysis assessing to determine if zoledronic acid prevents new clinical fractures published in the Osteoporosis International
- 01 May 2012 Actual end date changed from Nov 2006 to Feb 2007 as reported by ClinicalTrials.gov.
- 01 Sep 2011 Results published in Osteoporosis International.